Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis

Overview of attention for article published in JNCI: Journal of the National Cancer Institute, April 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

news: 3 news outlets
twitter: 5 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 14 Dimensions

Readers on

mendeley: 30 Mendeley

Summary News X Facebook Dimensions citations

So far, Altmetric has seen 3 news stories from 3 outlets.

Nonmetastatic CRPC Treatments Compared for Efficacy and Safety

MPR, 28 Apr 2021

Among treatments for nonmetastatic castration-resistant prostate cancer (nmCRPC), darolutamide may provide the best overall…

Nonmetastatic CRPC Treatments Compared for Efficacy and Safety

Renal & Urology News, 26 Apr 2021

Among treatments for nonmetastatic castration-resistant prostate cancer (nmCRPC), darolutamide may provide the best overall…

Nonmetastatic CRPC Treatments Compared for Efficacy and Safety

Cancer Therapy Advisor, 26 Apr 2021

Among treatments for nonmetastatic castration-resistant prostate cancer (nmCRPC), darolutamide may provide the best overall…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.